Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date08 Jun 2023 |
以安慰剂为平行对照评价参味宁郁片治疗抑郁症(气阴两虚证)有效性和安全性随机双盲单模拟、多中心临床试验
[Translation] A randomized double-blind, single-dummy, multicenter clinical trial to evaluate the efficacy and safety of Shenwei Ningyu tablets in the treatment of depression (Qi and Yin deficiency syndrome) with placebo as parallel control
进一步评价参味宁郁片治疗抑郁症(气阴两虚证)的有效性及安全性。
[Translation] To further evaluate the efficacy and safety of Shenwei Ningyu Tablets in the treatment of depression (Qi and Yin deficiency syndrome).
Efficacy and safety evaluation of Ningweiyixing in treatment for mild and moderate depression (qi and yin deficiency): A randomized, double-blind, double-dummy,placebo-controlled,fluoxetine-controlled multi-center Phase III clinical trial
100 Clinical Results associated with Guangdong Siji Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Guangdong Siji Pharmaceutical Co., Ltd.
100 Deals associated with Guangdong Siji Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Guangdong Siji Pharmaceutical Co., Ltd.